Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe
- A Coruña
- Frankfurt am Main
- Freiburg im Breisgau
- Halle (Saale)
- L'Hospitalet de Llobregat
- Le Mans
The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.
The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.
This study is to characterize the indications for which rituximab is being used and to evaluate the use of the Patient Alert Card (PAC) in participants receiving the medication for non-oncology conditions at infusion centers. The study involves the retrospective chart review of rituximab users' medical records in non-oncology indications as well as a survey to collect information on participant characteristics, and will include questions about participant knowledge on the risk of infections, participant receipt and review of the PAC, and any actions the participant has taken as a result of receiving the PAC.
MabThera Drug Utilisation Study and Patient Alert Card Evaluation in Non-Oncology Patients in Europe: An Infusion Centre-Based Approach
- Participant is in the center to receive an infusion for rituximab for a non-oncology indication during the study period
- Aged 18 years or older
- Has previously already completed the rituximab survey
- Has participated in the past 12 months in a clinical trial in which rituximab was one of the treatments being evaluated.
For the latest version of this information please go to www.forpatients.roche.com